• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    S

    Sansum Diabetes Research Institute

    EST. 1944
    380论文总数
    1.9万引用总数

    论文量&引用量时间轴

    机构学者

    论文(380)

    年份
    起
    –
    止
    排序
    1Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor.
    Laura M Nally,Jennifer L Sherr,Satish K Garg,Brynn E Marks,Lori M Laffel,Catherine Pihoker, Siham D Accacha, James R Thrasher,M Jennifer Abuzzahab, John H Reed,Laya Ekhlaspour, Sonali Belapurkar,

    INTRODUCTION:The present study assessed the impact of the disposable Simplera Sync™ sensor with the MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system on type 1 diabetes (T1D) glycemic metrics, insulin delivery, and safety. MATERIALS AND METHODS:Youths (aged 7-17 years) and adults (aged 18-80 years) with T1D were enrolled in this single-arm, nonrandomized study at 24 sites in the United States. Participants began with an ∼2-week run-in period where hybrid closed-loop (HCL; auto basal only) or open-loop insulin delivery was used, followed by an ∼3-month study period with AHCL activated. Glycemic outcomes and insulin delivery during the last 6-7 weeks of the study, when settings were optimized at investigator's discretion, were compared with the run-in. Glycemic outcomes with the use of recommended optimal settings (ROS, 100 mg/dL glucose target with a 2-h active insulin time) were explored. RESULTS:Time in automation was high (>93%) and mean time in range (TIR) increased from 54.4% ± 15.7% to 71.4% ± 9.9% (P < 0.001) in youths and from 66.5% ± 12.6% to 80.2% ± 8.1% (P < 0.001) in adults, primarily due to reduced time above range. Youths had a slight increase in time below range (TBR <70 mg/dL) from 1.6% ± 1.7% to 1.9% ± 1.4% (P < 0.001), while adults had no significant difference in TBR. For ROS users, TIR was 74.7% ± 9.3% in youths and 83.8% ± 7.4% in adults. Throughout the study ∼60% of total daily insulin dose was automated (auto basal and auto correction) in both cohorts. There were two cases of severe hypoglycemia and one episode of diabetic ketoacidosis (not related to the device). CONCLUSIONS:MM780G use with the Simplera Sync sensor is safe and demonstrated improved glycemic outcomes in both pediatric and adult participants with T1D, compared with the run-in period.

    2026Diabetes technology & therapeutics(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2Accuracy and Feasibility of Real-Time Continuous Glucose Monitoring in Early Postoperative Intensive Care after Liver Transplantation
    Marek Protus, Barbora Voglová Hagerf,Antonin Jabor, Janka Franekova, Lenka Nemetova, Eva Uchytilova, Veronika Indrova, Jana Beckova, Alex Macek, Martina Doleckova, Veronika Svirlochova,Milos Mraz,

    Background:Adequate glucose control is an important, yet a challenging task, in the early postoperative care after liver transplantation (LTx). Potential of continuous glucose monitoring (CGM) in this context had not been fully explored because of concerns about sensors' precision in critical care. Objectives:We initiated a trial to assess feasibility, accuracy, and benefit of CGM used in addition to standard blood glucose (BG) management. Design:Prospective randomized trial. Methods:Patients undergoing LTx were included and randomized to wearing (1) unblinded ("active") CGM which could help guiding insulin therapy, (2) blinded CGM serving as controls. Dexcom G6 was applied immediately after surgery, arterial BG values measured with blood gas analyzer served as reference and for calibration. We evaluated mean absolute relative difference (MARD), Diabetes Technology Society (DTS) Error Grid zones, bias, 15/15 agreement rate, evolvement of accuracy over time, and possible interfering factors. Fisher test, Mann-Whitney test, DTS software, and linear mixed model were used for statistical analysis. Results:We included 155 LTx recipients, 13 were excluded (1 died during surgery, 12 experienced sensor failure-6 from each group), data from 142 patients (80 in active and 62 in blinded CGM group) were analyzed. Overall, MARD was 9.1% in active and 10.7% in the blinded group (p < 0.0001). DTS error grid in active group had shown 90% in zone A versus 85.3% in the blinded group. These results were consistent for reference glucose ranges 3.9-10 mmol/L and above 10 mmol/L, with less precision in the low ranges (these values were however rare). Sensor accuracy peaked on days 2-3 and deteriorated over time with significant worsening from day 7 on in both groups. Conclusion:Our study demonstrates feasibility and acceptable accuracy of CGM comparable to reports from the outpatient care. We believe this could be attributed to sensor calibration, reflected by more favorable outcomes in the active CGM group. In addition, we demonstrate decline in accuracy over time, suggesting their use in critical care could be limited to less days to secure sufficient reliability. Trial registration:This study is part of an ongoing prospective trial registered on ClinicalTrials.gov (NCT05585801) and was registered on October 12, 2022.

    2026Therapeutic advances in endocrinology and metabolism(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3P-139: Performance of a NEXT-generation Algorithm for a Tubeless Automated Insulin Delivery System in Children with Type 1 Diabetes: Findings from the STRIVE Randomized Trial
    G Forlenza, D DeSalvo, L Laffel, A Criego, K Castorino, S MacLeish, D Raghinaru, R Beck, T Ly, J Sherr, STRIVE Consortium

    Abstract Introduction A recent randomized crossover trial compared a next-generation algorithm for Omnipod (Omnipod 6) with the first-generation Omnipod® 5 Automated Insulin Delivery System in a diverse population including adults (T1D/T2D) and children (T1D). Objectives This subgroup analysis assessed safety and efficacy within the vulnerable population of children with T1D who face elevated hypoglycemia risk. Methods This multicenter, randomized, crossover study compared Omnipod 6 at a 100mg/dL (5.6mmol/L) target with Omnipod 5 at a 110mg/dL (6.1mmol/L) target (4 weeks each) in current Omnipod 5 users. Users continued use of Omnipod 6 for an additional 4 weeks in a restricted bolus phase (goal of ≤3 boluses/day). Safety and efficacy outcomes were evaluated in children ages 2-<6 and 6-<14y. Results Children aged 2-<6y (n=29; age: 4±1y, baseline A1C: 7.0±0.8%) and 6-<14y (n=36; age: 11±2y, baseline A1C: 7.0±0.8%) with T1D were randomly assigned. The 100mg/dL target was used 82% and 95% of time in the 2-<6y and 6-<14y groups, respectively, with Omnipod 6. Time in tight range (70-140mg/dL) increased by 5.5% (+1.3h/d) with Omnipod 6 in those aged 6-<14y with no significant change in those aged 2-<6y. Time <54 and <70mg/dL remained low in both groups, meeting the non-inferiority margins of 0.75% and 3%, respectively (Table). A total of 63 children entered and completed the restricted bolus phase. TIR and TITR remained high with less boluses per day and algorithm insulin delivery increasing by a mean treatment group difference of 6% (4%, 8%) and 5% (2%, 7%), both p<0.001, vs. the Omnipod 6 phase in children 2-<6y and 6-<14y, respectively. No severe hypoglycemia or DKA events occurred. Conclusions These results demonstrate safety and strong efficacy potential of the next-generation Omnipod 6 algorithm in children with T1D as young as 2y.

    2026Hormone Research in Paediatrics(2026)
    引用
    AI阅读
    加入学术空间
    4Psychosocial Outcomes among Adults with Type 1 Diabetes Using a Tubeless Automated Insulin Delivery System Compared with Sensor Augmented Pump Therapy: A Randomised, Parallel-Group Clinical Trial Sub-Study.
    Jean-Pierre Riveline,Eric Renard,Grazia Aleppo,Bruce W Bode, Sue A Brown,Kristin Castorino, Irl B Hirsch, Mark S Kipnes, Lori M Laffel,Rayhan A Lal,Alfred Penfornis,Viral N Shah,

    AIMS:Beyond their glycaemic benefits, automated insulin delivery (AID) systems can provide psychosocial benefits for people with type 1 diabetes (T1D) and improve quality of life. In this study, we evaluated psychosocial outcomes in adults with T1D using the tubeless Omnipod® 5 AID System compared with sensor augmented pump (SAP) therapy. MATERIALS AND METHODS:As part of a 13-week multicentre, parallel-group, randomised controlled trial comparing intervention (tubeless AID) and control (SAP) groups (2:1), adults aged 18-70 years with T1D completed validated psychosocial questionnaires assessing health-related quality of life (European Quality of Life 5 Dimensions 3 Level Version [EQ-5D-3L] index score and visual analogue scale [VAS]), the impact of diabetes on quality of life (DAWN2 Impact of Diabetes Profile [DIDP]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), system usability (System Usability Scale [SUS]) and perceptions before and experiences after using AID systems (INsulin Dosing Systems: Perceptions, Ideas, Reflections and Expectations [INSPIRE]). RESULTS:The intervention group saw greater score improvements than the control group for all measures evaluated, including health-related quality of life (EQ-5D-3L VAS, p = 0.01; EQ-5D-3L index score, p = 0.002), impact of diabetes on quality of life (DIDP, p = 0.004), perceived system usability (SUS, p < 0.0001) and sleep quality (PSQI, p = 0.03). INSPIRE scores, determined only for the intervention group, were high at baseline and follow-up, suggesting positive perceptions of tubeless AID. CONCLUSIONS:This randomised controlled trial demonstrated that the use of a tubeless AID system improved psychosocial measures to a greater extent than SAP therapy. These results contribute to the growing body of evidence demonstrating that AID may improve quality of life and alleviate some of the burden associated with diabetes self-management in adults with T1D.

    2026Diabetes, obesity & metabolism(2026)
    引用
    AI阅读
    加入学术空间
    5Editorial: Diabetes and Pregnancy: Optimizing Maternal and Fetal Outcomes Through Advanced Technologies
    Grenye O'Malley, Cassandra E Henderson,Kristin Castorino
    2026Frontiers in endocrinology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 380 篇论文

    合作机构(100)

    加州大学圣塔巴巴拉分校合作论文 28
    弗吉尼亚大学合作论文 19
    Diabetes Technology Society合作论文 17
    斯坦福大学合作论文 15
    加州大学合作论文 14
    科罗拉多州立大学合作论文 12
    温纳贝戈医学中心合作论文 11
    帕多瓦大学合作论文 10
    哈佛大学合作论文 10
    加利福尼亚大学圣地亚哥分校合作论文 9

    机构统计